Lisette Sloots-Stork
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.
Journal: EJHaem
Published: April 09, 2021
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Journal: Breast cancer research and treatment
Published: July 21, 2017
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Journal: Annals of surgical oncology
Published: January 24, 2017
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Journal: Annals of surgical oncology
Published: June 20, 2016
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance.
Journal: Breast cancer research and treatment
Published: December 28, 2015
An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
Journal: Virchows Archiv : an international journal of pathology
Published: November 12, 2015
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.
Journal: Breast cancer research and treatment
Published: August 25, 2015
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
Journal: Breast care (Basel, Switzerland)
Published: July 22, 2015
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy.
Journal: Annals of surgical oncology
Published: April 14, 2015
Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
Journal: The oncologist
Published: January 07, 2015
Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
Journal: Annals of surgical oncology
Published: April 14, 2014
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Journal: Medical oncology (Northwood, London, England)
Published: April 01, 2014
Last Updated: 09/26/2026